Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 FY- Text added to 2022 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
abandoned, Alembic, anonymity, anti, antigen, appellate, Arab, Arabia, Atlantic, bacterium, blocker, BoNTE, brick, broader, Chancery, chimeric, Cliff, cohort, conflict, convenient, counterfeit, curtailed, cyber, Deputy, diffuse, discretionary, diverted, DJS, docetaxel, dosage, durable, EPCORE, escalated, extreme, eyelash, fibrotic, flu, follicular, formulary, forthcoming, geopolitical, greatly, GSK, Helicobacter, HEPTAD, hiring, humanitarian, hybrid, illegal, illegally, image, increasingly, infraorbital, infusion, injector, internet, jawline, Juvise, Katcher, Latisse, lenalidomide, lesser, lieu, macroeconomic, media, mentoring, mortar, motor, Multnomah, Nakata, nationwide, NCCN, Network, networking, Notice, Oregon, peptic, Perry, play, Poor, PRAC, prevalence, prohibited, prophylactic, Pulmonary, pursuit, Pylera, pylori, Ranney, Reddy, redesign, rehearing, remanded, SA, Saudi, scott, spondyloarthropathy, stolen, suspended, synaptic, Syndesi, traditional, transmembrane, Treaty, Treppel, Ukraine, unregistered, upgraded, vehicle, vesicle, Volbella, Volux
Removed:
accretion, activator, Amgen, AML, appeal, appointment, Aptinyx, ASU, bardoxolone, bleeding, Cadila, competitively, contemplated, debate, decade, dismissal, dose, drawn, elagolix, estradiol, exit, facilitated, FASB, Fe, frequency, FZE, generalized, gland, GnRH, Gosebruch, heavy, Henry, inadequately, intraperiod, Laura, low, lowered, lowering, luteinizing, menstrual, methotrexate, methyl, Modernization, NaN, neurological, Nomination, nonpeptide, notch, obinutuzumab, observed, omaveloxolone, orilissa, ovarian, palsy, permitted, pituitary, pretax, productivity, profile, progesterone, PsA, pustular, putative, rank, reacquired, Reata, redeemed, removing, responded, rovalpituzumab, Schumacher, Severino, sex, side, signaling, SLL, sum, Sun, suppression, terminate, terminated, tesirine, Topic, tranche, unsubordinated, untreated, venclyxto, whichever, worked
Valuein 2021 FY filing- Value in 2022 FY filing
Original filings
Filing view